Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-16, Stock:NVO, The news for the past five days is as follows:
2018-01-08: NEWS1: Novo Nordisk Makes $3.1 Billion Takeover Offer For Ablynx.NEWS2: CBMG Up 90% In 5 Days, ALDR Delivers On Promise, ABLX Being Pursued By NVO.NEWS3: CBMG Up 90% In 5 Days, ALDR Delivers On Promise, ABLX Being Pursued By NVO.NEWS4: Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid.NEWS5: Ablynx soars after rejects Novo Nordisk's $3.1 bln biotech bid.NEWS6: Novo Nordisk revises up offer for Ablynx to $3.1 billion.NEWS7: Novo Nordisk revises up offer for Ablynx to $3.1 billion.NEWS8: Novo Nordisk Makes Unsolicited Bid for Ablynx.NEWS9: [$$] Belgium's Ablynx Rejects Novo Nordisk Bid.NEWS10: Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018.NEWS11: How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?.NEWS12: In Drug Deals, $3.1 Billion Isn't Exactly Full-Blooded.NEWS13: ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS.NEWS14: Novo Nordisk bids $3.1 billion for Belgian biotech group Ablynx.NEWS15: Novo Nordisk submits proposal to buy biopharmaceutical fi....NEWS16: Ablynx Says Novo Nordisk's Offer Undervalues The Company And Future Prospects.NEWS17: Ablynx Says Novo Nordisk's Offer Undervalues The Company And Future Prospects.NEWS18: Novo Goes Public With $3.1 Billion Bid to Pressure Ablynx.NEWS19: Novo Nordisk Urges Ablynx To Consider EUR 2.6 Bln Offer.NEWS20: Novo Nordisk Urges Ablynx To Consider EUR 2.6 Bln Offer.
2018-01-09: NEWS1: Novo Nordisk Confirms Bid for Ablynx But Faces Rejection.NEWS2: Ozempic® approved in Canada for the treatment of adults with type 2 diabetes.NEWS3: Ozempic® approved in Canada for the treatment of adults with type 2 diabetes.NEWS4: [$$] Belgium’s Ablynx Rejects Novo Nordisk Bid.
2018-01-10: NEWS1: Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know.NEWS2: Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know.NEWS3: Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes.NEWS4: Novo Nordisk&apos;s Ozempic Gets Canadian Approval for Diabetes.
2018-01-11: NEWS1: Why is Novo Nordisk Stock Up More Than 50% in Past Year?.NEWS2: Why is Novo Nordisk Stock Up More Than 50% in Past Year?.NEWS3: How Is Bioverativ’s Eloctate Positioned Now?.NEWS4: How Is Roche’s Hemlibra Positioned for 2018?.
2018-01-12: NEWS1: Three Diabetes Clinical Trials to Watch in 2018.NEWS2: Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference.NEWS3: Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference.

Answer: Rise